Prof William Symmans speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about a multi-centre pooled analysis looking at residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer.
He explains that after 6 months of chemotherapy it can be difficult to report cancer due to the way it alters tumours in many ways meaning it's important to standardise approaches in reporting back to the surgeon, oncologist and the patient.
Prof Symmans reports that residual cancer burden actually had a linear relationship with the risk of the disease returning.
Watch his press conference here.
Read more about the study here.